Macquarie Group Ltd. cut its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 23.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 980,046 shares of the company’s stock after selling 291,972 shares during the period. Macquarie Group Ltd. owned 0.11% of Teva Pharmaceutical Industries worth $49,228,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of TEVA. Natixis raised its position in shares of Teva Pharmaceutical Industries by 62.0% in the first quarter. Natixis now owns 5,197 shares of the company’s stock worth $278,000 after buying an additional 1,988 shares during the period. Panagora Asset Management Inc. raised its position in shares of Teva Pharmaceutical Industries by 216.5% in the first quarter. Panagora Asset Management Inc. now owns 702,480 shares of the company’s stock worth $37,590,000 after buying an additional 480,509 shares during the period. Seven Eight Capital LLC raised its position in shares of Teva Pharmaceutical Industries by 783.3% in the first quarter. Seven Eight Capital LLC now owns 31,800 shares of the company’s stock worth $1,702,000 after buying an additional 28,200 shares during the period. Euclid Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 2.4% in the first quarter. Euclid Advisors LLC now owns 169,332 shares of the company’s stock worth $9,061,000 after buying an additional 4,001 shares during the period. Finally, One Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries by 10.0% in the first quarter. One Capital Management LLC now owns 27,281 shares of the company’s stock worth $1,460,000 after buying an additional 2,479 shares during the period. Institutional investors own 63.00% of the company’s stock.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) traded down 0.85% on Friday, hitting $38.56. The stock had a trading volume of 6,477,070 shares. Teva Pharmaceutical Industries Ltd. has a 52 week low of $37.82 and a 52 week high of $66.55. The stock has a market capitalization of $39.14 billion, a P/E ratio of 22.43 and a beta of 0.73. The firm has a 50-day moving average price of $43.93 and a 200-day moving average price of $50.26.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.29 by $0.02. Teva Pharmaceutical Industries had a return on equity of 16.75% and a net margin of 8.81%. The company had revenue of $5.56 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same period last year, the firm posted $1.35 earnings per share. Teva Pharmaceutical Industries’s revenue was up 15.3% compared to the same quarter last year. Equities analysts expect that Teva Pharmaceutical Industries Ltd. will post $5.16 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 20th. Investors of record on Monday, December 5th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, December 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.53%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently 50.58%.

TEVA has been the subject of several analyst reports. Oppenheimer Holdings Inc. upgraded shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $66.00 price target for the company in a report on Friday, September 2nd. Vetr upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating and set a $60.02 price target for the company in a report on Monday, August 1st. Leerink Swann set a $57.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Friday, October 7th. Morgan Stanley set a $63.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Monday, September 12th. Finally, Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. Thirteen equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $60.00.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.